Bristol-myers Squibb Compnay

Pfizer Corporation

Genentech, Inc.

Cytomx Therapeutics, Inc.

The Rockefeller University

Genetech, Inc.

Brigitte Devaux

Haichun Huang

Peter Brams

Kristopher Toy

Paul O Sheppard

Arvind Rajpal

Daniel F Ardourel

Alan J Korman

Mark J Selby

Guodong Chen

Heidi N Leblanc

Michelle Minhua Han

Ronald P Gladue

Huiming Li

Ekaterina G Deyanova

Xiao Min Schebye

Christine Bee

Lan Yang

Barrett Richard Thiele

Andy X Deng

Anan Chuntharapai

Rory Francis Finn

Yanli Wu

Wei Liao

Yi Wu

Jing Min

Timothy J Paradis

Aaron Paul Yamniuk

Richard Y Huang

Brenda L Stevens

Bryan C Barnhart

Michelle Renee Kuhne

Shannon Lee Okada

Hong-An Truong

Jun Zhang

Mohan Srinivasan

Dan L Eaton

J Kevin Judice

Daniel Kirchhofer

Camellia W Adams

Philip E Hass

David B Passmore

Karla Ann Henning

Mark F Maurer

Indrani Chakraborty

Tetsuya Ishino

Tseng-hui Timothy Chen

Robert Arch

Joel Bard

Susan H Julien

Shelley Suggett

William Finlay

Orla Cunningham

Ciara Reilly

Madhav Narasimha Devalaraja

Leonard G Presta

James William West

David L Shelton

Jo-Anne Hongo

Steven Lee Bender

Haibin Chen

Hartmut Koeppen

Mark Yamanaka

Dawn M Tanamachi

Michael Aidan North

Gerald Fries Casperson

Gilbert-Andre Keller

Gang Li

Xin Jiang

Dana Dan Hu-Lowe

Tim Sproul

Jianying Wang

Grant Wickman

Lawrence A Lasky

Jeffrey V Ravetch

Richard Yu-Cheng Huang

Leonard Presta

Rony Dahan

Michelle M Mader

Michelle Kuhne

Michelle Mader

Hong-An Troung

Michelle Madar

Tim W Sproul

Jo-Anne S Hongo

Ronald Paul Gladue

Timothy Joseph Paradis

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Anti-CD40 antibodies and uses thereof

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligandA(TLA) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TLA mediated diseases, disorders or conditions.

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Nucleic acids encoding an anti-CD40 antibody

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Antibodies to CD40 with enhanced agonist activity

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

Growing community of inventors

Palo Alto, CA, United States of America

Brigitte Devaux